Scale up of proteoliposome derived Cochleate production

Vaccine. 2006 Apr 12:24 Suppl 2:S2-94-5. doi: 10.1016/j.vaccine.2005.01.139.

Abstract

Cochleate are highly stable structures with promising immunological features. Cochleate structures are usually obtaining from commercial lipids. Proteoliposome derived Cochleate are derived from an outer membrane vesicles of Neisseria meningitidis B. Previously, we obtained Cochleates using dialysis procedures. In order to increase the production process, we used a crossflow system (CFS) that allows easy scale up to obtain large batches in an aseptic environment. The raw material and solutions used in the production process are already approved for human application. This work demonstrates that CFS is very efficient process to obtain Cochleate structures with a yield of more than 80% and the immunogenicity comparable to that obtained by dialysis membrane.

MeSH terms

  • Adjuvants, Immunologic / isolation & purification*
  • Adjuvants, Immunologic / pharmacology
  • Animals
  • Female
  • Mice
  • Neisseria meningitidis, Serogroup B* / chemistry
  • Proteolipids / isolation & purification*
  • Proteolipids / pharmacology
  • Ultrafiltration

Substances

  • Adjuvants, Immunologic
  • Proteolipids
  • proteoliposomes